Objective: To investigate the clinical characteristics of pityriasis rosea in children after COVID-19 vaccination. Methods: The data of cases with pityriasis rosea from August 2020 to March 2022 who were diagnosed with pityriasis rosea after vaccination were analyzed, including detailed history, physical examination, blood count, eosinophil count, etc.. Results: Twenty-one children were included in the analysis, including 9 males and 12 females, with a mean age of 9.48±2.14 years. Of the 19 children who provided vaccine details, 63.2% (12/19) developed a rash after receiving the first dose and 31.6% (6/19) developed a rash after receiving the second dose. The average time to rash after vaccination is 6±3.67 days, and the average duration of rash was 41.6±23.97 days. Conclusion: Pityriasis rosea is a mild, self-limiting skin adverse event that occurs after vaccination against COVID-19.